Weiss Ratings Reaffirms “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating reissued by equities researchers at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other equities research analysts have also recently issued research reports about the stock. Chardan Capital lowered their target price on shares of 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 11th. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, February 10th. Bank of America lowered their target price on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Morgan Stanley lowered their target price on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. Finally, Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.13.

4D Molecular Therapeutics Trading Down 1.3 %

4D Molecular Therapeutics stock opened at $4.67 on Wednesday. 4D Molecular Therapeutics has a 12 month low of $4.41 and a 12 month high of $36.25. The business’s 50 day simple moving average is $5.42 and its 200 day simple moving average is $9.07. The company has a market cap of $215.89 million, a price-to-earnings ratio of -1.64 and a beta of 2.81.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently added to or reduced their stakes in FDMT. Vanguard Group Inc. grew its position in shares of 4D Molecular Therapeutics by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company’s stock valued at $15,933,000 after acquiring an additional 92,791 shares during the period. State Street Corp grew its position in shares of 4D Molecular Therapeutics by 1.8% during the 3rd quarter. State Street Corp now owns 2,116,508 shares of the company’s stock valued at $22,879,000 after acquiring an additional 37,232 shares during the period. Assenagon Asset Management S.A. grew its position in shares of 4D Molecular Therapeutics by 238.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock valued at $16,684,000 after acquiring an additional 1,087,147 shares during the period. Novo Holdings A S grew its position in shares of 4D Molecular Therapeutics by 7.1% during the 3rd quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $16,215,000 after acquiring an additional 100,000 shares during the period. Finally, Millennium Management LLC grew its position in shares of 4D Molecular Therapeutics by 1,607.1% during the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock valued at $7,913,000 after acquiring an additional 1,337,497 shares during the period. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.